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Background: The negative factor (Nef) of human and simian immunodeficiency
viruses (HIV-1, HIV-2 and SIV) is required for high levels of viremia and
progression to AIDS. Additionally, Nef leads to cellular activation, increased viral
infectivity and decreased expression of CD4 on the cell surface. Previously, we
and others demonstrated that Nef associates with a cellular serine kinase (NAK)
activity. Recently, it was demonstrated that NAK bears structural and functional
similarity to p21-activated kinases (PAKs).
Results: In this study, we demonstrate that Nef not only binds to but also activates
NAK via the small GTPases CDC42 and Rac1. First, the dominant-negative PAK
(PAKR), via its GTPase-binding domain, and dominant-negative GTPases
(CDC42Hs-N17 and Rac1-N17) block the ability of Nef to associate with and
activate NAK. Second, constitutively active small GTPases (CDC42Hs-V12 and
Rac1-V12) potentiate the effects of Nef. Third, interactions between Nef and NAK
result in several cellular effector functions, such as activation of the serum-
response pathway. And finally, PAKR, CDC42Hs-N17 and Rac1-N17 decrease
levels of HIV-1 production to those of virus from which the nef gene is deleted.
Conclusions: By activating NAK via small GTPases and their downstream
effectors, Nef interacts with regulatory pathways required for cell growth,
cytoskeletal rearrangement and endocytosis. Thus, NAK could participate in the
budding of new virions, the modification of viral proteins and the increased
endocytosis of surface molecules such as CD4. Moreover, blocking the activity
of these GTPases could lead to new therapeutic interventions against AIDS.
Background
Unlike classical oncogenic retroviruses, the genomes of
HIV-1, HIV-2 and SIV contain several additional genes
besides those encoding Gag, Pol and Env polyprotein pre-
cursors [1]. Protein products of these additional genes play
important roles in different stages of the viral life cycle
[1,2]. One of these is a myristoylated 27 kDa membrane-
associated protein called Nef [3,4]. Despite earlier contro-
versies [5–11], it has become clear that Nef plays an
important role in viral pathogenesis. In the simian model
of acquired immune deficiency syndrome (AIDS), the nef
gene is essential for high levels of viremia and progression
to AIDS [12]. Additionally, viruses from infected human
long-term non-progressors (who do not manifest the symp-
toms of AIDS) often contain deletions in the conserved
region of the nef gene [13,14]. However, the molecular
basis for this Nef phenotype remains poorly understood.
Previously, we and others demonstrated that Nef co-
immunoprecipitates with two phosphoproteins, p62 and
p72, known as Nef-associated kinase (NAK) activity
[15–17]. Recently, it was suggested that NAK shares
epitopes with p21-activated kinases (PAKs) [17]. In that
study, antibodies against the amino-terminal 20 amino acids
and the carboxy-terminal 19 amino acids of rat PAK1 —
anti-PAK(N20) and anti-PAK(C19), respectively — could
re-immunoprecipitate a phosphoprotein of 65 kDa that had
previously been co-immunoprecipitated with epitope-
tagged Nef protein, and that had the same mobility as their
immunoprecipitated NAK [17]. Moreover, the substrate
specificity of this NAK was similar to that of PAK.
However, no direct association between Nef and a known
PAK could be demonstrated, and no signalling or functional
correlates with viral replication were presented [17].
In this study, we found that p62 and p72 are also
recognized by some anti-PAK antibodies, that Nef not
only associates with but also activates NAK, that this acti-
vation occurs via the small GTPases CDC42 and Rac1,
and that this process activates the serum-response
pathway. Moreover, dominant-negative forms of PAK
(PAKR) and GTPases (CDC42Hs-N17 and Rac1-N17)
decreased the levels of viral production in cells to those
observed with virus from which the nef gene was deleted.
Thus, the GTPases CDC42 and Rac1 play pivotal roles in
effects of Nef in infected cells.
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Results
Nef activates NAK, which bears structural similarity to PAK,
in cells
To determine whether p62 and p72, like p65 [17], are
recognized by anti-PAK antibodies, we performed the
experiments presented in Figure 1. The p62 and p72 pro-
teins are found in complexes that are immunoprecipitated
by anti-Nef antibodies from T cells and are phosphory-
lated on serine residues in an in vitro kinase assay [15,16].
In our hands, anti-PAK(N20), but not anti-PAK(C19),
antibodies could recognize NAK in complexes obtained
from Jurkat cells that stably expressed the CD8–Nef
fusion protein; phosphorylation of NAK was detected by
performing an in vitro kinase assay on the immunoprecipi-
tates (Fig. 1a, lanes 2,4; Fig. 1b, lanes 2,4). Although
human PAK65 (hPAK65) itself was not activated by Nef
in these cells (Fig. 1c, lane 2), anti-PAK(C19) could recog-
nize a constitutively active form of hPAK65 expressed in
Jurkat cells (PAKE; Fig. 1c, lane 3 and Fig. 1d). However,
if we first disrupted the anti-Nef immunoprecipitates and
then added the anti-PAK(C19) antibody, then NAK was
also recognized by this antibody, in agreement with
published results (data not shown) [17]. These results
confirm that NAK bears structural similarity to PAK,
suggest that epitopes in the carboxy-terminal part of NAK
are not accessible to antibodies when NAK is in the Nef
complex, and reveal that Nef not only binds to but also
activates NAK. That NAK is not a known PAK was also
confirmed by transient expression assays in COS cells and
by in vitro transcription and translation experiments,
which failed to demonstrate a direct association between
Nef and known isoforms of PAK (PAK1, PAK2 and PAK3)
(data not shown) [18–20]. Additionally, patterns of tryptic
peptides obtained from PAKE and p62 (Fig. 1) were not
identical (data not shown) [17]. The same results were
obtained with cells infected with HIV-1.
Sequences in the amino and carboxyl termini are
conserved among known PAKs [18–20]. The amino-termi-
nal half of PAK (residues 1–249) is its regulatory domain,
which binds to CDC42 and Rac1 via its GTPase-binding
domain (residues 72–89) (Fig. 1d). Because the carboxy-
terminal kinase domain (residues 250–525) is even more
conserved among known PAKs, it is somewhat surprising
that anti-PAK(C19) did not recognize NAK, and that the
reactivity of anti-PAK(C19) appeared to be less than that
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Figure 1
NAK activity is stimulated by Nef and
recognized by some, but not all, anti-PAK
antibodies in in vitro kinase assays. (a) Kinase
activity was associated with p62 and p72 in
anti-Nef and anti-PAK(N20) immuno-
precipitates only from Jurkat cells that stably
expressed the CD8–Nef fusion protein (JCN
cells; lanes 2 and 4); CD8–Nef consists of Nef
and the extracellular and transmembrane
domains of CD8 [38]. No kinase activity was
detected in either type of immunoprecipitate
from parental Jurkat cells (lanes 1 and 3). (b)
The anti-CD8 antibody immunoprecipitated
CD8–Nef and NAK activity from JCN cells, but
not from Jurkat cells (lanes 3 and 4); the anti-
PAK(C19) antibody did not immunoprecipitate
NAK activity from either cell line (lanes 1 and
2). (c) The anti-PAK(C19) antibody
immunoprecipitated a constitutively active form
of hPAK65 (PAKE; see (d)) from Jurkat cells
transfected with a plasmid encoding PAKE
(PAKE; lane 3). Moreover, hPAK65 was not
activated by Nef in Jurkat cells that were
transiently transfected with a plasmid encoding
CD8–Nef (CN; lane 2). (d) Diagrammatic
representation of hPAK65, PAKE, PAKR and
PAKR-LL. hPAK65 is 525 amino-acids long;
the amino-terminal 249 amino acids and the
carboxy-terminal 276 amino acids are
regulatory and catalytic (kinase) domains,
respectively [18,19]. The GTPase-binding
domain (GBD) is located between residues 72
and 89 [18,19]. The amino-terminal 20 amino
acids and the carboxy-terminal 19 amino acids,
which are recognized by anti-PAK(N20) and
anti-PAK(C19) antisera, respectively, are
depicted by lines below hPAK65 [17]. hPAKE
is a constitutively active PAK65, in which the
threonine residue at position 403 is mutated to
a glutamic acid (T403E). PAKR is a dominant-
negative form of hPAK65 and contains the
amino-terminal 225 amino acids of hPAK65
[35]. PAKR-LL is identical to PAKR, except 
that the two histidine residues at positions 84
and 87 are substituted by leucines (H84L,
H87L), which decreases its interactions with
the small GTPases.
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of anti-PAK(N20) [17]. However, as will become apparent,
NAK behaves structurally and functionally like a PAK
(see below).
The activation of NAK by Nef occurs via CDC42 and Rac1
Because NAK is antigenically related to PAK, we next
tested the ability of PAKR (Fig. 1d; [18]), to block the
activation of NAK by Nef. CD8–Nef and PAKR proteins,
which were co-expressed in Jurkat cells, were
immunoprecipitated with the anti-CD8 antibody and
subjected to in vitro kinase assays. As seen in Figure 2a
(lane 2, top panel), PAKR prevented the co-immunopre-
cipitation of active p62 and p72 with Nef. This result was
confirmed in COS cells, where interactions between Nef
and p62 were also blocked by PAKR in a dose-dependent
manner (Fig. 2b, top panel, lanes 4–6). Note that, in
contrast to Jurkat cells, only p62 was seen in COS cells, as
described previously [15,16]. Thus, it is possible that p72
is a lymphocyte-specific substrate for NAK. Because the
levels of the CD8–Nef fusion protein were not affected
(Fig. 2a,b, bottom panels), and the control luciferase
activity expressed from the RSV LTR promotor was
unchanged (data not shown), the inhibition of NAK was
not a non-specific effect of PAKR. Moreover, PAKR-LL
(Fig. 1d), which has a lower affinity for CDC42 and Rac1
(A. Abo, data not shown), did not inhibit the
phosphorylation of p62 as efficiently as did PAKR (Fig. 2c,
lanes 2,3). The same result was obtained using wild-type
Nef from simian immunodeficiency virus (SIV; Fig. 2e).
These data suggest that CDC42 and Rac1 are involved in
Nef’s association with and activation of NAK.
To investigate this role of CDC42 and Rac1 directly, we co-
expressed CD8–Nef with constitutively active and domi-
nant-negative CDC42 (CDC42Hs-V12 and CDC42-N17,
respectively) and/or Rac1 (Rac1-V12 and Rac1-N17, respec-
tively) in COS cells. Indeed, CDC42Hs-N17, Rac1-N17 or
both blocked the activity of NAK (Fig. 3a, lanes 4–12). In
sharp contrast, CDC42Hs-V12 and Rac1-V12 increased the
activity of NAK in the presence of Nef (Fig. 3b, lanes 2,3)
and they overcame the inhibition of NAK by PAKR (Fig.
3b, lanes 6,8). In parallel experiments, constitutively active
and dominant-negative forms of RhoA (RhoA-V14 and
RhoA-N19, respectively) had no effect on NAK (data not
shown). Thus CDC42 and/or Rac1, but not RhoA, are
required for  Nef to associate with and activate NAK.
Research Paper  Nef activates NAK via Rac1 and CDC42 Lu et al. 1679
Figure 2
PAKR inhibits Nef’s association with and
activation of NAK via its GTPase-binding
domain. (a) PAKR blocks the activation of
NAK by Nef in Jurkat cells. Anti-Nef
immunoprecipitates from transfected Jurkat
cells were subjected to in vitro kinase assays
(top panel); cells expressed the CD8–Nef
protein alone (lane 3) or with PAKR (lane 2).
As in Fig. 1, NAK was not activated in cells
that did not express Nef (lane 1). As
demonstrated by western blotting, the levels
of expression of the CD8–Nef were constant
(lower panel, lanes 2 and 3). HC and LC
denote heavy and light chains of the
antibodies, respectively. CN above the top
panel denotes cell transfected with the
plasmid encoding CD8–Nef, and in the lower
panel it denotes the expressed CD8–Nef
protein. (b) PAKR inhibits the activation of
NAK by Nef in COS cells. Cells were
transfected with increasing amounts of
plasmid encoding PAKR, as depicted by the
black triangle (lanes 4–6: 0, 2 and 5 mg,
respectively), or with plasmid encoding
CD8–Nef, as noted above the top panel.
Levels of expression of CD8–Nef were
constant, as detected by western blotting
(lower panel, lanes 2,4,5,6). (c) Mutations in
the GTPase binding domain abolish the
inhibitory effects of PAKR. PAKR (lane 2), but
not PAKR-LL (lane 3), blocked Nef’s
association with and activation of NAK, as
detected by the in vitro kinase assay. The p62
in COS cells expressing only CD8–Nef is
seen in lane 1. (d) As demonstrated by
western blotting, the levels of expression of
PAKR-LL were four-fold higher than those of
PAKR. The levels of CD8–Nef expression
were constant (data not shown). (e) PAKR
also inhibits the activation of NAK by wild-type
SIV Nef in COS cells. Increasing amounts of
plasmid encoding PAKR (black triangle; 0, 2
and 5 mg) were co-expressed with constant
amounts (2 mg) of SIV Nef (Nef-wt), and the
phosphorylation of p62 was examined using
the in vitro kinase assay. The levels of Nef
were constant (data not shown).
(a)
–	 +	 –
–	 +	 +
PAKR
CN
(b)
–	 –	 +
–	 +	 –	 +	 +	 +
(c) –	 –	 +
+	 +	 +
–	 +	 –
PAKR-LL
PAKR
CN
Kinase assay
Kinase assay
Western blot
Kinase assay
Kinase assay
Western blot
p72
p62
p62
HC
CN
LC
p72
CN
1	 2	 3
1	 2	 3
1	 2	 3	 4	 5	 6
(e)(d)
1	 2	 3	 4
PA
KR
Co
ntr
ol
PA
KR
-LL
1	 2	 3
–
–	 +	 +	 +
PAKR
Nef-wt
Western blot
To confirm that small GTPases are required to activate
NAK, we transiently expressed Nef in parental Rat1
fibroblasts and in Rat1 cells stably expressing CDC42Hs-
V12 (Rat1/CDC42Hs-V12 cells). As seen in Figure 3c, the
activity of NAK was more than 20 times higher in
Rat1/CDC42Hs-V12 cells than in parental Rat1 cells
(compare lanes 4 and 6). Thus, the activity of the small
GTPases is limiting and, when CDC42Hs-V12 is
expressed, Nef is able to associate with more NAK, or
NAK is more active in the Nef complex. Finally, the
individual components of the NAK complex could be
assembled in vitro (Fig. 3d). Recombinant Nef and
CDC42Hs were incubated with GTPgS and lysates from
Jurkat cells for the complete reconstitution of NAK activ-
ity in a cell-free system (Fig. 3d, lanes 3,4). This activation
was GTP-dependent, as substitution of GTPgS with
GDPgS resulted in the loss of phosphorylation of p62 (data
not shown). Because recombinant hPAK65 did not substi-
tute for lysates from Jurkat cells (data not shown), these
lysates most probably provided the serine kinase and its
protein substrates. We conclude that Nef associates with
and activates NAK via CDC42 and Rac1.
Nef activates the serum-response pathway via CDC42 and
Rac1 in cells
Small GTPases, including CDC42 and Rac1, are also
involved in the activation of the serum-response pathway
[21,22]. To determine if proteins that interact with the
serum-response element (SRE) are the downstream
effectors of NAK, we co-expressed Nef with a plasmid
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Figure 3
Effects of different mutants of CDC42 and
Rac1 on the association with and activation of
NAK by Nef in COS cells. (a) CDC42Hs-N17
and Rac1-N17 block the effects of Nef on
NAK. The results of in vitro kinase assays on
anti-Nef immunoprecipitates from the desig-
nated cells are shown in the top panel. Lane 1,
parental COS cells; lanes 2–12, COS cells
co-expressing CD8–Nef together with
plasmid vector (lane 2), PAKR (lane 3),
increasing amounts of CDC42Hs-N17 (lanes
4–6), increasing amounts Rac1-N17 (lanes
7–9) and increasing amounts of both
CDC42Hs-N17 and Rac1-N17 (lanes 10–12).
The lower panel shows the levels of CD8–Nef
expressed in the COS cells, as detected by
western blot analysis of the gel in the top
panel. (b) CDC42Hs-V12 and Rac1-V12 over-
come the inhibition by PAKR. The results of
the in vitro kinase assay are shown in the top
panel. Lanes 1–3, COS cells co-expressing
CD8–Nef together with vector control (lane 1),
CDC42Hs-V12 (lane 2) or Rac1-V12 (lane 3);
lane 4, parental COS cells; lanes 5–8, COS
cells co-expressing CD8–Nef and PAKR
together with vector control (lanes 5,7),
CDC42Hs-V12 (lane 6) or Rac1-V12 (lane 8).
The lower panel shows the levels of expression
of CD8–Nef (see (a)). (c) The activity of NAK
is greatly potentiated in cells stably expressing
CDC42Hs-V12. In vitro kinase assays (top
panel) were performed on immunoprecipitates
from cells that did not express Nef (lanes
1,3,5), or that expressed CD8–Nef (lanes
2,4,6). Lanes 1 and 2, COS cells; lanes 3 and
4, parental Rat1 cells; lanes 5 and 6, Rat1
cells stably expressing CDC42Hs-V12. The
lower panel shows the levels of expression of
CD8–Nef (see (a)). (d) NAK is activated by
recombinant Nef and CDC42 in vitro. Nef and
CDC42Hs produced in the baculovirus system
were incubated with GTPgS and lysates from
Jurkat cells. Both recombinant proteins were
required to activate NAK (p62) in this
reconstituted system (lanes 3,4). Neither
protein alone (Nef, lanes 2,5; CDC42Hs, lane
1) could activate NAK. Lysates from Jurkat
cells are required as the source of the serine
kinase and its protein substrates. PPT refers to
the treatment of Nef with l-phosphatase
before the in vitro kinase reactions. Lane 6 and
7 represent controls for the l-phosphatase
and lysate, respectively.
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target that contained five SREs 5′ of the TATA box and
the firefly luciferase reporter gene in NIH 3T3 cells. The
level of luciferase activity in these cells was five-fold
higher in the presence of Nef (Fig. 4a, bars 3,4). More-
over, the mutant Nef, in which two arginine residues at
positions 109 and 110 were substituted by leucines, and
which no longer associates with and activates NAK [16],
failed to activate the serum-response pathway (bar 5). The
activation via SREs was blocked by PAKR (Fig. 4a, bar 6)
as well as by CDC42Hs-N17 and Rac1-N17 (bar 7); thus,
the situation was similar to that seen with NAK. As
expected, the activation by serum was also inhibited by
PAKR (Fig. 4a, bars 9,10). At present, we do not know if
the serum-response factor (SRF) or ELK-1, both of which
are required for the binding to and activation of the SRE
[21,22], are the targets of this activation. We conclude that
the activation of the serum-response pathway by Nef also
depends on CDC42, Rac1 and NAK.
Dominant-negative forms of PAK and GTPases block viral
production in cells
To determine whether CDC42 and Rac1 might be
responsible for the increased levels of viral replication in
the presence of Nef, we studied the contributions of these
small GTPases on the replication of HIV-1 by measuring
the levels of the p24Gag antigen in the cell culture super-
natants. The HIV-1 (BRU3 strain) proviral DNA was intro-
duced alone or with a plasmid encoding PAKR into COS
cells [23,24]; an isogenic provirus lacking the nef gene was
used as the control. We consistently found that the levels of
p24Gag were between four- and five-fold lower with the
nef-deleted virus (Fig. 4b, compare bars 1 and 5). Because
this phenotype was rescued by co-expressing Nef from a
separate plasmid (Fig. 4b, bar 6), this decreased synthesis of
HIV-1 was due to the absence of the nef gene. Moreover,
when the wild-type provirus was co-expressed with PAKR,
the levels of p24Gag were reduced to those observed with
the nef-deleted provirus (Fig. 4b, bar 2). The co-expression
of CDC42Hs-N17 and Rac1-N17 resulted in a similar
decrease in the level of HIV-1 production (Fig. 4b, bar 3).
Moreover, in cells that stably expressed PAKR, we
detected little to no viral replication (data not shown).
Neither PAKR nor CDC42Hs-N17 and Rac1-N17 had any
effect on the nef-deleted virus (data not shown). Thus,
CDC42 and Rac1 are required for optimal levels of Nef-
dependent viral replication in vivo.
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Figure 4
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Effects of Nef on transcriptional regulation and viral replication. (a) Nef
activates the serum-response pathway. Luciferase activity was
measured in mock-transfected NIH3T3 cells (mock); in NIH3T3 cells
transfected with the plasmid target (5XSRE luciferase; –) alone; in NIH
3T3 cells transfected with 5XSRE luciferase and plasmids encoding
Nef, CD8–Nef (CN), CD8–Nef in which two arginines were changed
to leucines (R109L, R110L; CN-RR), or equivalent amounts of the
CD8–Nef and PAKR proteins; and in NIH 3T3 cells transfected with
5XSRE together with plasmids encoding CD8–Nef, Rac1-N17 and
CDC42Hs-N17, or the SRF–VP16 fusion protein. All of the above
transfected cells were maintained in serum-free media. The black bars
show the levels of luciferase activity in NIH3T3 cells grown in medium
containing 15 % fetal calf serum and transfected with
5XSRE luciferase alone or together with a plasmid encoding PAKR.
Fold-activation indicates the luciferase levels in extracts from cells co-
transfected with the plasmid target and effectors relative to the basal
level (defined as 1) observed with 5XSRE luciferase alone. Values are
presented schematically (bars) and numerically (numbers above the
bars). (b) PAKR, CDC42Hs-N17 and Rac1-N17 inhibit HIV-1
replication in cells. The levels of p24Gag were measured by enzyme-
linked immunosorbent assay (ELISA) in cell supernatants from COS
cells expressing the HIV-1 (BRU) provirus with an intact nef gene
(black bars) or HIV-1 (BRU) provirus with a deletion of the nef gene
(white bars). The COS cells were transfected with 3 mg DNA
encoding PAKR, 3 mg each of plasmids encoding CDC42Hs-N17 and
Rac1-N17, or 3 mg of plasmids encoding PAK65 or Nef, as indicated.
Standard errors of the mean for three transfections performed in
parallel are indicated. 
Discussion
Our data confirm that NAK is immunologically and
functionally related to PAK [17]. In addition, they show
that Nef activates NAK via CDC42 and Rac1, resulting in
the activation of downstream cellular effector functions.
Furthermore, the inhibition of the viral production by
PAKR and dominant-negative CDC42 or Rac1 indicates
that NAK is required for optimal levels of viral replication
in vivo.
On the basis of our results, NAK could be a new isoform of
PAK. Although NAK, like PAK, is also under the control
of CDC42 and Rac1, Nef and known isoforms of PAK do
not associate in cells. Moreover, in sharp contrast to consti-
tutively active CDC42 and Rac1 proteins, neither consti-
tutively active hPAK1 (hPAKL107F) nor hPAK65 (PAKE)
proteins restored the activity of NAK blocked by PAKR.
Finally, two-dimensional tryptic peptide maps of p62 and
PAKE were different (data not shown).
The significance of the activation of the serum-response
pathway by Nef is not clear. However, it is possible that this
activation changes the milieu of the infected cell leading to
higher levels of viral production. In this regard, it is inter-
esting to note that Nef from SIV isolate pbj14 transforms
and leads to the serum-independent growth of 3T3 cells
[25]. Our results suggest that HIV-1 Nef has similar, albeit
weaker effects in the same cells.
Our viral production assay measures de novo synthesis
and/or release of viral particles in transfected cells. It does
not include the steps of reverse transcription and integra-
tion that are thought to be the target of Nef in the viral
infectivity assay described by Miller et al. [26]. However,
our preliminary results failed to detect any involvement of
Rac1 and CDC42 in the viral infectivity assays in CD4-
expressing HeLa cells (data not shown). This discrepancy
could result from an inability to package these small
GTPases into the virion. We conclude that the augmenta-
tion of viral production adds another layer of complexity to
the function of Nef in the viral life cycle.
How does Nef activate NAK? One possibility is that Nef
activates an upstream effector of both small GTPases
and/or stimulates an exchange factor (Fig. 5). A good
example of a protein that might be activated by Nef is the
human oncogene Dbl, which is an exchange factor for
CDC42 [27]. Alternatively, Nef could trap an active form of
NAK that is activated constitutively by CDC42 and Rac1.
At present, we cannot distinguish between these possibili-
ties. However, differences between these pathways might
be important for other downstream effector functions, such
as the effects of CDC42 on the cytoskeleton, and of  Rac1
on endocytosis (Fig. 5); see below.
The Rho family GTPases, including CDC42 and Rac1,
play major roles in the cytoskeletal rearrangement in
response to a variety of stimuli in organisms as diverse as
yeast and mammals [28,29]. In yeast, CDC42 and its
downstream effector Ste20, which is equivalent to PAK in
humans, play a central role in the response to mating
pheromones and budding [30–32]. In Drosophila, CDC42
and Rac1 and their direct effector DPAK have been impli-
cated in the dorsal closure, a developmental process that
requires actin assembly and disassembly [33]. In
mammals, these small GTPases are involved in the forma-
tion of filopodia, lamellipodia and membrane ruffling [34].
Moreover, several effectors for the mammalian CDC42
and Rac1 have been identified. The best studied exam-
ples include human PAKs, rat PAKs and WASP (Wiscott–
Aldrich syndrome protein). WASP is important for the
polymerization of actin and for T-cell activation [29],
whereas PAKs play a critical role in the activation of the
JNK pathway [35]. Recent studies have suggested an
additional role for CDC42 and Rac1 in the endocytosis of
certain receptors in mammalian cells [36].
All these effectors could be potential targets of Nef. By
activating small GTPases, Nef could facilitate the viral
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Figure 5
Model for the role of CDC42 and Rac1 in the activation of NAK and HIV-
1 replication. Interactions between Nef and NAK are essential for viral
replication. Furthermore, Nef’s association with and activation of NAK is
dependent on the activation of GTPases CDC42 and Rac1. It is
possible that Nef stimulates a GTP/GDP exchange factor to activate
CDC42 and Rac1 (indicated by the question mark). Alternatively
CDC42 and Rac1 may play a role in the activation of NAK by inducing
the association between NAK and Nef. Activation of NAK by Nef may
lead to higher viral replication through the SRE pathway. Finally, CDC42
can activate the Wiscott-Aldrich syndrome protein (WASP), which leads
to the rearrangement in the actin cytoskeleton [29]. These latter effects
might also promote the budding of virions from the infected cells.
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budding process, or the endocytosis of surface proteins
such as CD4; or it could affect virion morphology and
composition by phosphorylating viral structural proteins,
such as the matrix protein [37]. This study of Nef and
small GTPases has elucidated a novel aspect of viral
replication. In the host, interfering with this signalling
cascade should decrease levels of viremia and might con-
tribute to the treatment of AIDS. With the cloning and
further characterization of NAK, a unified and compre-
hensive model that could explain many phenotypes of
Nef may be on the horizon.
Materials and methods
Tissue culture and in vitro kinase assays
Cells that express the wild-type Nef or CD8–Nef fusion proteins were
lysed and their proteins immunoprecipitated with anti-Nef, anti-
PAK(N20), anti-CD8 or anti-PAK(C19) antibodies. Stable cell lines
were maintained, and immunoprecipitations and in vitro kinase assays
were performed as described previously [15,16,38]. Transient expres-
sion assays were performed using lipofectamine (GIBCO/BRL,
Gaithersburg, Maryland) and cells were harvested 48 h after transfec-
tions. COS cells expressed from 2 mg of plasmid encoding CD8–Nef
(pCN; Figs 2 and 3), increasing amounts (0.1 1, and 2 mg) of plasmids
encoding PAKR, CDC42Hs-N17 or Rac1-N17, and 2 mg of PAKR-LL.
Rat1/CDC42Hs-V12 cells were created by transfecting Rat1 cells with
pCVN expression vectors, which direct the synthesis of CDC42Hs-
V12, and selecting them with 400 mg ml–1 of G418. pCT (encoding
CD8) and pCN (encoding CD8–Nef) [38] were then transfected into
the cells. The transfected cells expressing either combination of pro-
teins were analyzed. For western blotting, proteins were transferred
from SDS–PAGE gels onto Immobilon membranes and probed with
the anti-Nef antibody, as described previously [38].
In vitro reconstitution experiments
The cDNA encoding HIV-1 Nef, which contains the Glu–Glu epitope at
the amino terminus, was cloned into a baculovirus expression system,
as described previously [18]. Recombinant Nef (5 mg) and CDC42Hs
(5 mg), which was preloaded with GTPgS, and lysates from Jurkat cells
(5 × 105 cell equivalents) were incubated for 2 h. Other combinations
are described in the legend to Figure 3d. Nef was immunoprecipitated
with the anti-Glu–Glu monoclonal antibody and subjected to the in
vitro kinase assay [15,16]. To remove any phosphorylated proteins,
which might be associated with Nef, the recombinant Nef was treated
with l-phosphatase (PPT 2,3,4,5; New England BioLabs, Cambridge,
Massachusetts) for 30 min according to manufacturer’s instructions.
Twice the amount of lysate was included in Fig. 3d, lanes 3 and 5.
Serum-response assay
NIH 3T3 cells were maintained in DMEM medium containing 10 % fetal
calf serum (FCS). Before transfections, the cells were starved for 6 h in
serum-free media. Cells were then transfected with 0.5 and 4 mg of
plasmid targets and effectors, respectively, using lipofectamine
(GIBCO/BRL, Gaithersburg, Maryland). Transfected cells were main-
tained in the serum-free medium for 24 h, lysed, and luciferase assays
were performed. For the serum control, 15 % FCS was added to the
medium after transfection. Values represent the average of three inde-
pendent transfections performed in parallel, where the standard error of
the mean was less than 15 %. 5XSRE luciferase was a generous gift
from S. An. This fragment, which contained five copies of the SRE from
the c-fos promoter, the E1b TATA box and the firefly luciferase gene,
was cloned into pGL-3 (Promega Biotech, Madison, Wisconsin).
HIV-1 production assays
COS cells were transfected with indicated plasmids using lipofectamine
(GIBCO/BRL), as above. 48 h later, supernatants from transfected cells
were filtered using 0.45 mm Acrodiscs (Gelman Sciences, Ann Arbor,
Missouri) and serial dilutions were assayed for levels of p24Gag by
ELISA (Coulter, Hialeah, Florida). The concentrations (in pg ml–1) were
calculated using an internal standard provided with the kit. Both the HIV-
1 provirus and the HIV-1 provirus with a deletion in the nef gene
(between nucleotides 8390 and 8661, a region between the env gene
and 3′ LTR with no other known function) were kindly provided by K.
Peden and M. Emerman.
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